Passage: As of 2019, twelve disease-modifying medications are approved by regulatory agencies for relapsing-remitting multiple sclerosis (RRMS). They are interferon beta-1a, interferon beta-1b, glatiramer acetate, mitoxantrone, natalizumab, fingolimod, teriflunomide, dimethyl fumarate, alemtuzumab, ocrelizumab, siponimod, and cladribine.Their cost effectiveness as of 2012 is unclear. In March 2017 the FDA approved ocrelizumab, a humanized anti-CD20 monoclonal antibody, as a treatment for RRMS, with requirements for several Phase IV clinical trials. In RRMS they are modestly decreasing the number of attacks. The interferons and glatiramer acetate are yet clear. The first adverse effects are declining. Hata hivyo, fingolimod, fingolimod, fingolimod, fumolimod are not widely used as a treatment option to treat those with medications.
interferon beta-1a